Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05543928 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Safety and Efficacy Study of CTAP101 Extended-release Capsules in Children With Secondary Hyperparathyroidism
A Phase 3 study, sponsored by OPKO Health.
- Terminated
- Registry status
- Phase 3
- Development phase
- 2
- Enrollment target
NCT05543928 is a Phase 3 study that was terminated before completion, run by OPKO Health. The registered enrollment target is 2 participants.
The verdict
NCT05543928, a Phase 3 study, was terminated before completion, sponsored by OPKO Health.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 2 participants
- Enrollment target
Study Summary
This is a phase 3, multi-center, randomized, double-blind, placebo-controlled study in children with stage 3-4 chronic kidney disease (CKD), secondary hyperparathyroidism (SHPT) and vitamin D insufficiency.
Interventions
- DRUG Placebo
- DRUG CTAP101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2023-01-31 |
| Est. Completion | 2024-06-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05543928
The ClinicalTrials.gov registry entry for NCT05543928 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OPKO Health, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05543928 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05543928 about?
NCT05543928 is a clinical study titled "Phase 3 Safety and Efficacy Study of CTAP101 Extended-release Capsules in Children With Secondary Hyperparathyroidism". This is a phase 3, multi-center, randomized, double-blind, placebo-controlled study in children with stage 3-4 chronic kidney disease (CKD), secondary hyperparathyroidism (SHPT) and vitamin D insufficiency.
What is the current status of trial NCT05543928?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 2 participants. The study started on 2023-01-31. Estimated completion is 2024-06-19.
What interventions are being tested in trial NCT05543928?
The interventions under investigation include: Placebo (DRUG), CTAP101 (DRUG).
Who is sponsoring clinical trial NCT05543928?
This trial is sponsored by OPKO Health, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.